| Active Not Recruiting | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Thera NCT03719131 | Emory University | Phase 2 |
| Completed | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partn NCT03112668 | Rutgers, The State University of New Jersey | N/A |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Terminated | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02748564 | Rutgers, The State University of New Jersey | Phase 2 |
| Withdrawn | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplifica NCT02812693 | Joanne Jeter | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Emory University | Phase 1 |
| Completed | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine NCT02716948 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases NCT02941744 | Universitair Ziekenhuis Brussel | Phase 1 / Phase 2 |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, NCT02318771 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Bee NCT02320305 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Mel NCT01970527 | University of Washington | Phase 2 |
| Completed | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrol NCT01789827 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma NCT01961115 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Remove NCT01886235 | Roswell Park Cancer Institute | N/A |
| Completed | Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma NCT01960634 | Grupo Español Multidisciplinar de Melanoma | — |
| Terminated | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma NCT01744171 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Unknown | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma NCT02654821 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Me NCT01307618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and T NCT01196416 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma NCT00866177 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Recombinant Interferon Alfa-2b in Treating Patients With Melanoma NCT01460875 | William Carson | N/A |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma NCT00397982 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma NCT00387751 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV NCT00110019 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has NCT01989559 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma NCT00026221 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma NCT00019682 | National Cancer Institute (NCI) | Phase 3 |